Avanos Medical Inc (AVNS)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	—	226,300	—	—	—	130,000	145,000	165,000	175,000	180,000	—	—	—	248,100	247,900	247,800	247,900
Total stockholders’ equity	US$ in thousands	1,236,300	1,222,100	1,234,800	1,298,700	1,291,200	1,263,500	1,259,000	1,262,800	1,270,600	1,267,100	1,301,700	1,257,400	1,262,100	1,289,900	1,261,600	1,256,500	1,272,600	1,266,900	1,276,900	1,280,100
Debt-to-equity ratio		0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	0.10	0.11	0.13	0.14	0.14	0.00	0.00	0.00	0.19	0.20	0.19	0.19

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,236,300K
= 0.00

The debt-to-equity ratio of Avanos Medical Inc has shown some fluctuation over the past eight quarters. In Q4 2023, the company's debt-to-equity ratio was 0.14, indicating a relatively low level of debt compared to equity. This suggests that the company has a strong equity position relative to its debt in this period.

Looking at the trend over the past quarters, we can observe that the ratio increased from Q1 2023 to Q3 2023, reaching a peak of 0.22 in Q3 2023. However, it then decreased in Q4 2023 to 0.14. Despite these fluctuations, the debt-to-equity ratio has generally remained relatively stable between 0.16 and 0.22 over the last two years.

Overall, a lower debt-to-equity ratio indicates that the company is relying more on equity financing rather than debt to fund its operations, which can be seen as a positive sign of financial stability and lower financial risk. However, it is important to monitor future changes in the ratio to assess the company's ongoing financial health and capital structure.